ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study.

Paolo Strati,Michelle A. Fanale,Yasuhiro Oki,Francesco Turturro,Luis E Fayad,Nancy L. Bartlett,Douglas E. Gladstone,Yvette L. Kasamon,Carol S. Portlock,Wyndham H. Wilson,Andre Goy,Anas Younes,Hun Ju Lee

user-5f8cf7e04c775ec6fa691c92（2019）

引用 11|浏览2

暂无评分

摘要

Based on several randomized studies comparing doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with other multi-drug regimens, ABVD is the standard of care for newly diagnosed, advanced stage, classical Hodgkin lymphoma (cHL).[1][1] While the cure rate with ABVD approximates 75% in

查看译文

关键词

ABVD,Dacarbazine,Vinblastine,Rituximab,Bleomycin,Phases of clinical research,Doxorubicin,Randomized controlled trial,Oncology,Medicine,Internal medicine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要